All In Biotech

Drug Trial Radar · NCT02113982

Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia

Tagraxofusp in Patients With Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Last checked: Nov 20, 2026Latest source record: Aug 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

138

Actual

Start

Sep 2014

Primary completion

Feb 1, 2020

Study completion Mar 12, 2020

Sponsor

Lead sponsor
Stemline Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
The Leukemia and Lymphoma Society
First posted
Apr 15, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 4-stage, non-randomized, open-label, dose escalation and expansion, multicenter study. A cycle of therapy is 21 days. Stage 1 was a dose-escalation stage. During Stages 2-4, patients are treated at the MTD or maximum tested dose at which multiple DLTs are not observed during Stage 1.

Conditions

  • Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
  • Acute Myeloid Leukemia (AML)

Interventions

  • TagraxofuspDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MTD (Stage 1)Time frame: 21-day period after the first dose (cycle 1)
  2. CR Rate in First-line BPDCN (Stage 3, Pivotal Cohort)Time frame: at pre-defined treatment cycle intervals from randomization up to disease progression, up to 3.5 years

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California

  • H. Lee Moffiitt Cancer Center & Research Institute

    Tampa, Florida

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Columbia University Medical Center

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Ohio State University

    Columbus, Ohio

  • University of Pittsburgh Medical Center Presbyterian Shady Side

    Pittsburgh, Pennsylvania

  • MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.